LAUSR

Nowadays fungal infection emerged as a significant problem to healthcare management systems due to the high frequency of associated morbidity and mortality and the limitations like toxicity, drug-drug interactions, and resistance of the currently available antifungal agents. Aspergillus is the most common mold which causes infection in immunocompromised hosts. It is a hyaline mold that is cosmopolitan and ubiquitous. Aspergillus infects around 10 million population each year with a mortality rate of 30-90%. Clinically available antifungal formulations are restricted to four classes (i.e., polyene, triazole, echinocandin, and allylamine), and each of them have their limitations associated with the activity spectrum, the emergence of resistance, and toxicity. Consequently, novel antifungal agents with modified and altered chemical structures are required to combat these invasive fungal infections. To overcome these limitations, there is an urgent need for new antifungal agents that can act as potent drugs in near future. Currently, some compounds have been shown effective antifungal activity. In this review article, we have discussed all potential antifungal therapies that contain old antifungal drugs, combination therapies, and recent novel antifungal formulations, with a focus on the Aspergillus-associated infections.